Windtree Therapeutics, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
WINT Company Description
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
WINT Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view WINT Smart Score
Score Breakdown
WINT Company Description
Show More
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of WINT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by WINT's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of WINT in WallStreetBets Daily Discussion
WINT News
Recent insights relating to WINT
CNBC Recommendations
Recent picks made for WINT stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in WINT
Corporate Flights
Flights by private jets registered to WINT
Our Analysis